Adirondack Trust Co. Sells 52 Shares of Becton, Dickinson and Company (NYSE:BDX)

Adirondack Trust Co. decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 4.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,151 shares of the medical instruments supplier’s stock after selling 52 shares during the period. Adirondack Trust Co.’s holdings in Becton, Dickinson and Company were worth $278,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Jennison Associates LLC boosted its holdings in shares of Becton, Dickinson and Company by 4.9% in the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after buying an additional 18,786 shares in the last quarter. Norden Group LLC boosted its stake in Becton, Dickinson and Company by 2,086.7% in the first quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after acquiring an additional 49,559 shares in the last quarter. Franklin Street Advisors Inc. NC purchased a new position in Becton, Dickinson and Company in the first quarter worth $11,998,000. Avity Investment Management Inc. grew its holdings in Becton, Dickinson and Company by 3.5% in the first quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock worth $40,257,000 after purchasing an additional 5,527 shares during the last quarter. Finally, Caden Capital Partners LP increased its position in shares of Becton, Dickinson and Company by 26.7% during the fourth quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock worth $20,340,000 after purchasing an additional 17,599 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.4 %

BDX stock opened at $238.21 on Thursday. The company has a market capitalization of $68.84 billion, a P/E ratio of 52.47, a price-to-earnings-growth ratio of 1.92 and a beta of 0.42. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $269.52. The firm’s fifty day simple moving average is $236.55 and its 200-day simple moving average is $235.45. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.96 earnings per share. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were given a $0.95 dividend. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Wall Street Analyst Weigh In

BDX has been the topic of several research analyst reports. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Raymond James decreased their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.